Lyell Immunopharma Inc is a clinical-stage cell therapy company... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
LYEL is expected to report earnings to rise 3.44% to -17 cents per share on August 06
Q2'25
Est.
$-0.17
Q1'25
Est.
$-0.17
Q4'24
Missed
by $0.51
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.18
The last earnings report on May 13 showed earnings per share of -16 cents, beating the estimate of -17 cents. With 786.67K shares outstanding, the current market capitalization sits at 169.70M.